BCNU (Carmustine): Revision history

From Glioblastoma Treatments
Jump to navigationJump to search

Diff selection: Mark the radio buttons of the revisions to compare and hit enter or the button at the bottom.
Legend: (cur) = difference with latest revision, (prev) = difference with preceding revision, m = minor edit.

12 November 2024

30 March 2024

  • curprev 20:4220:42, 30 March 2024Lazy talk contribs 2,138 bytes +2,138 Created page with "{{TreatmentInfo |drug_name=BCNU (Carmustine) |FDA_approval=Yes, approved for treatment of brain tumors, multiple myeloma, Hodgkin's disease, and non-Hodgkin's lymphomas |used_for=Recurrent Glioblastoma Multiforme (GBM) after radiation treatment |clinical_trial_phase=Various, given its long history of use |common_side_effects=Hepatic and pulmonary toxicity, myelosuppression |OS_without=Not specified in the provided context |OS_with=Not specified in the provided context |P..."